Leerink on BioMarin Pharma (BMRN): 'We continue to hold a more cautious view on the outlook for Voxzogo'
March 9, 2026 2:38 PM
Leerink Partners analyst Joseph Schwartz reiterated a Market Perform rating and $62.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
